Section Arrow
Quote
ATTO.NASDAQ
- Attovia Therapeutics Inc
Quotes are at least 15-min delayed:2026/09/22 02:58 EDT
Regular Hours
Last
 21.3
-0.84 (-3.79%)
Day High 
22.455 
Prev. Close
22.14 
1-M High
28 
Volume 
460.93K 
Bid
21
Ask
28
Day Low
20.21 
Open
22.31 
1-M Low
18.85 
Market Cap 
1.01B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 23.27 
20-SMA 22.31 
50-SMA -- 
52-W High 28 
52-W Low 16.1501 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.64/-2.38
Enterprise Value
1.01B
Balance Sheet
Book Value Per Share
-3.19
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.35M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.97+0.14+3.66%-- 
MRNAModerna172.94+18.9+12.27%-- 
SLXNSilexion Therapeutics Corp.0.5441+0.1086+24.94%-- 
CELZCreative Medical Technology Holdings1.005+0.0391+4.05%-- 
PDSBPDS Biotechnology Corp0.8419+0.0364+4.52%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.